[Current state and the future of molecular target drugs: lessons learned from the success of imatinib].
Yamada
Hisashi
H
hyamad@jikei.ac.jp
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D055808:Drug Discovery / Q000639:trends; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl; D018390:Gene Targeting; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl